Acacia patent expiration

1. Barhemsys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(9 years from now)

US11357753 ACACIA Rescue treatment of post operative nausea and vomiting
Feb, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 27 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting; Prevention and treatment of post-operative nausea and vomiting

Dosage: SOLUTION

More Information on Dosage

BARHEMSYS family patents

Family Patents

2. Byfavo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 06, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 06 October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER

More Information on Dosage

BYFAVO family patents

Family Patents